Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catabasis Pharma (CATB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,870
  • Shares Outstanding, K 29,030
  • Annual Sales, $ 500 K
  • Annual Income, $ -27,360 K
  • 36-Month Beta 0.56
  • Price/Sales 37.92
  • Price/Cash Flow N/A
  • Price/Book 0.43
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/09/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.22
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +48.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.61 +6.56%
on 08/06/18
0.89 -26.97%
on 07/16/18
-0.20 (-23.53%)
since 07/13/18
3-Month
0.61 +6.56%
on 08/06/18
1.76 -63.07%
on 06/04/18
-0.99 (-60.37%)
since 05/14/18
52-Week
0.61 +6.56%
on 08/06/18
3.78 -82.80%
on 10/04/17
-0.54 (-45.38%)
since 08/14/17

Most Recent Stories

More News
Catabasis Pharmaceuticals Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Catabasis Pharmaceuticals Inc (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern...

CATB : 0.65 (unch)
Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate...

CATB : 0.65 (unch)
Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2018 financial results before the NASDAQ Global Market open on...

CATB : 0.65 (unch)
Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy

-- Phase 2 MoveDMD(R) Trial and Open-Label Extension Showed Substantially Slowed Duchenne Disease Progression in Patients Treated with Edasalonexent --

CATB : 0.65 (unch)
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Manitowoc Company, Inc....

MTW : 22.89 (-0.04%)
CATB : 0.65 (unch)
ZAYO : 37.65 (+0.43%)
SGEN : 74.63 (+1.12%)
OMER : 20.62 (+7.51%)
CVA : 17.25 (-0.86%)
Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD(R) Trial

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement...

CATB : 0.65 (unch)
Catabasis Pharmaceuticals, Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Showing Early Clinical Success

NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

CATB : 0.65 (unch)
Catabasis Pharmaceuticals Announces Closing of $42M Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an...

CATB : 0.65 (unch)
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.

PTCT : 44.89 (+4.06%)
SLDB : 39.02 (+1.43%)
CATB : 0.65 (unch)
SRPT : 124.87 (-1.83%)
PFE : 40.71 (-0.25%)
Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering

Catabasis Pharmaceuticals, Inc. ("Catabasis," the "Company," "we," "our," or "us") (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten...

CATB : 0.65 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CATB with:

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

2nd Resistance Point 0.69
1st Resistance Point 0.67
Last Price 0.65
1st Support Level 0.63
2nd Support Level 0.61

See More

52-Week High 3.78
Fibonacci 61.8% 2.57
Fibonacci 50% 2.19
Fibonacci 38.2% 1.82
Last Price 0.65
52-Week Low 0.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar